Kazia Therapeutics (KZIA) vs Tenax Therapeutics (TENX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kazia Therapeutics (KZIA) has outperformed Tenax Therapeutics (TENX) over the past year, losing 41.1% versus a loss of 84.7%. Over five years, KZIA leads with a -99.0% price change compared with -99.9% for TENX. Tenax Therapeutics is the larger company by market cap ($56.9 million vs $56.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KZIA | TENX |
|---|---|---|
| Share price | $4.92 | $1.25 |
| Market cap | $56.22M | $56.92M |
| 1-day change | -8.38% | -10.07% |
| YTD return | -28.59% | -89.75% |
| 1-year return | -41.08% | -84.66% |
| 5-year return | -99.01% | -99.94% |
| EPS (TTM) | $-6.85 | $-1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | — | $-52.60M |
| 52-week high | $17.40 | $19.40 |
| 52-week low | $4.50 | $1.24 |
| Distance from 52-week high | -71.72% | -93.56% |
| Analyst consensus | none | none |
| Avg. price target upside | +476.02% | +904.80% |
| Average volume | 307.30K | 3.15M |
| Shares outstanding | 11.43M | 45.54M |
| Employees | 6 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KZIA has outperformed TENX by 43.6 percentage points over the past year.
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Tenax Therapeutics
TENX stock →Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
KZIA vs TENX FAQ
Which is bigger, Kazia Therapeutics or Tenax Therapeutics?
Tenax Therapeutics (TENX) is larger, with a market capitalization of $56.92M compared with $56.22M for Kazia Therapeutics (KZIA).
Which stock has performed better over the past year, KZIA or TENX?
KZIA returned -41.08% over the past 12 months, compared with -84.66% for TENX (price return, excluding dividends). Past performance does not predict future results.
Are Kazia Therapeutics and Tenax Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.